BRP-187: A potent inhibitor of leukotriene biosynthesis that acts through impeding the dynamic 5-lipoxygenase/5-lipoxygenase-activating protein (FLAP) complex assembly

Biochemical Pharmacology

Volumn 119, Issue , 2016, Pages 17-26

  Garscha, Ulrike ^a   Voelker, Susanna ^a   Pace, Simona ^a   Gerstmeier, Jana ^a   Emini, Besa ^a   Liening, Stefanie ^a   Rossi, Antonietta ^b   Weinigel, Christina ^c   Rummler, Silke ^c   Schubert, Ulrich S ^a   Scriba, Gerhard K E ^a   Çelikoğlu, Erşan ^d   Çalışkan, Burcu ^d   Banoglu, Erden ^d   Sautebin, Lidia ^b   Werz, Oliver ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c JENA UNIVERSITY HOSPITAL   (Germany)

^d GAZI UNIVERSITY   (Turkey)

Author keywords

5 Lipoxygenase; 5 Lipoxygenase activating protein; Arachidonic acid; Inflammation; Leukotriene

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 4 (4 CHLOROPHENYL) 5 [4 (QUINOLIN 2 YLMETHOXY)PHENYL]ISOXAZOL 3 CARBOXYLIC ACID; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN INHIBITOR; ARACHIDONIC ACID; CALCIMYCIN; FORMYLMETHIONYLLEUCYLPHENYLALANINE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOPOLYSACCHARIDE; LIPOXYGENASE INHIBITOR; PROSTAGLANDIN E SYNTHASE 1; UNCLASSIFIED DRUG; ZILEUTON; BRP-187; HYDROXYUREA; INDOLE DERIVATIVE; ISOXAZOLE DERIVATIVE; LEUKOTRIENE; MK-886; QUINOLINE DERIVATIVE; ZYMOSAN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL NUCLEUS MEMBRANE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME SUBSTRATE COMPLEX; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MONOCYTE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NORMAL HUMAN; PERITONEUM EXUDATE; PRIORITY JOURNAL; PROTEIN TRANSPORT; TREATMENT OUTCOME; ZYMOSAN-INDUCED PERITONITIS; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; CELL FREE SYSTEM; CHEMICAL STRUCTURE; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; METABOLISM; PERITONITIS;

5-LIPOXYGENASE-ACTIVATING PROTEINS; ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; CELL-FREE SYSTEM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEK293 CELLS; HUMANS; HYDROXYUREA; INDOLES; ISOXAZOLES; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; MALE; MICE; MOLECULAR STRUCTURE; PERITONITIS; QUINOLINES; ZYMOSAN;

EID: 84991231223     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2016.08.023     Document Type: Article

References (58)

1. [1] Peters-Golden, M., Henderson, W.R. Jr., Leukotrienes. N. Engl. J. Med. 357 (2007), 1841–1854.
2. [2] Radmark, O., Werz, O., Steinhilber, D., Samuelsson, B., 5-Lipoxygenase, a key enzyme for leukotriene biosynthesis in health and disease. Biochim. Biophys. Acta 2015 (1851), 331–339.
3. [3] Pergola, C., Werz, O., 5-Lipoxygenase inhibitors: a review of recent developments and patents. Expert Opin. Ther. Pat. 20 (2010), 355–375.
4. [4] Fourie, A.M., Modulation of inflammatory disease by inhibitors of leukotriene A4 hydrolase. Curr. Opin. Investig. Drugs 10 (2009), 1173–1182.
5. [5] Kleinschmidt, T.K., Haraldsson, M., Basavarajappa, D., Lundeberg, E., Thulasingam, M., Ekoff, M., et al. Tandem benzophenone amino pyridines, potent and selective inhibitors of human leukotriene C4 synthase. J. Pharmacol. Exp. Ther. 355 (2015), 108–116.
6. [6] Becker, A., Leukotriene receptor antagonists: efficacy and safety in children with asthma. Pediatr. Pulmonol. 30 (2000), 183–186.
7. [7] Beierschmitt, W.P., McNeish, J.D., Griffiths, R.J., Nagahisa, A., Nakane, M., Amacher, D.E., Induction of hepatic microsomal drug-metabolizing enzymes by inhibitors of 5-lipoxygenase (5-LO): studies in rats and 5-LO knockout mice. Toxicol. Sci. 63 (2001), 15–21.
8. [8] Evans, J.F., Ferguson, A.D., Mosley, R.T., Hutchinson, J.H., What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases. Trends Pharmacol. Sci. 29 (2008), 72–78.
9. [9] Gerstmeier, J., Weinigel, C., Barz, D., Werz, O., Garscha, U., An experimental cell-based model for studying the cell biology and molecular pharmacology of 5-lipoxygenase-activating protein in leukotriene biosynthesis. Biochim. Biophys. Acta 2014 (1840), 2961–2969.
10. [10] Pettersen, D., Davidsson, O., Whatling, C., Recent advances for FLAP inhibitors. Bioorg. Med. Chem. Lett. 25 (2015), 2607–2612.
11. [11] Gerstmeier, J., Weinigel, C., Rummler, S., Radmark, O., Werz, O., Garscha, U., Time-resolved in situ assembly of the leukotriene-synthetic 5-lipoxygenase/5-lipoxygenase-activating protein complex in blood leukocytes. FASEB J. 30 (2016), 276–285.
12. [12] Mandal, A.K., Jones, P.B., Bair, A.M., Christmas, P., Miller, D., Yamin, T.T., et al. The nuclear membrane organization of leukotriene synthesis. Proc. Natl. Acad. Sci. 105 (2008), 20434–20439.
13. [13] Mancini, J.A., Abramovitz, M., Cox, M.E., Wong, E., Charleson, S., Perrier, H., et al. 5-Lipoxygenase-activating protein is an arachidonate binding protein. FEBS Lett. 318 (1993), 277–281.
14. [14] Gerstmeier, J., Newcomer, M.E., Dennhardt, S., Romp, E., Fischer, J., Werz, O., et al. 5-Lipoxygenase-activating protein rescues activity of 5-lipoxygenase mutations that delay nuclear membrane association and disrupt product formation. FASEB J., 2016, 1892–1900.
15. [15] Fischer, L., Hornig, M., Pergola, C., Meindl, N., Franke, L., Tanrikulu, Y., et al. The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5-lipoxygenase products. Br. J. Pharmacol. 152 (2007), 471–480.
16. [16] Abramovitz, M., Wong, E., Cox, M.E., Richardson, C.D., Li, C., Vickers, P.J., 5-Lipoxygenase-activating protein stimulates the utilization of arachidonic acid by 5-lipoxygenase. Eur. J. Biochem. 215 (1993), 105–111.
17. [17] Dixon, R.A., Diehl, R.E., Opas, E., Rands, E., Vickers, P.J., Evans, J.F., et al. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 343 (1990), 282–284.
18. [18] Rouzer, C.A., Ford-Hutchinson, A.W., Morton, H.E., Gillard, J.W., MK886, a potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5-lipoxygenase in ionophore-challenged leukocytes. J. Biol. Chem. 265 (1990), 1436–1442.
19. [19] Ferguson, A.D., McKeever, B.M., Xu, S., Wisniewski, D., Miller, D.K., Yamin, T.T., et al. Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein. Science 317 (2007), 510–512.
20. [20] Banoglu, E., Caliskan, B., Luderer, S., Eren, G., Ozkan, Y., Altenhofen, W., et al. Identification of novel benzimidazole derivatives as inhibitors of leukotriene biosynthesis by virtual screening targeting 5-lipoxygenase-activating protein (FLAP). Bioorg. Med. Chem. 20 (2012), 3728–3741.
21. [21] Banoglu, E., Celikoglu, E., Volker, S., Olgac, A., Gerstmeier, J., Garscha, U., et al. 4,5-Diarylisoxazol-3-carboxylic acids: A new class of leukotriene biosynthesis inhibitors potentially targeting 5-lipoxygenase-activating protein (FLAP). Eur. J. Med. Chem. 113 (2016), 1–10.
22. [22] Fischer, L., Szellas, D., Radmark, O., Steinhilber, D., Werz, O., Phosphorylation- and stimulus-dependent inhibition of cellular 5-lipoxygenase activity by nonredox-type inhibitors. FASEB J. 17 (2003), 949–951.
23. [23] Steinhilber, D., Herrmann, T., Roth, H.J., Separation of lipoxins and leukotrienes from human granulocytes by high-performance liquid chromatography with a Radial-Pak cartridge after extraction with an octadecyl reversed-phase column. J. Chromatogr. 493 (1989), 361–366.
24. [24] Koeberle, A., Siemoneit, U., Buhring, U., Northoff, H., Laufer, S., Albrecht, W., et al. Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1. J. Pharmacol. Exp. Ther. 326 (2008), 975–982.
25. [25] Schaible, A.M., Koeberle, A., Northoff, H., Lawrenz, B., Weinigel, C., Barz, D., et al. High capacity for leukotriene biosynthesis in peripheral blood during pregnancy. Prostaglandins Leukotrienes Essent. Fatty Acids 89 (2013), 245–255.
26. [26] Schaible, A.M., Filosa, R., Krauth, V., Temml, V., Pace, S., Garscha, U., et al. The 5-lipoxygenase inhibitor RF-22c potently suppresses leukotriene biosynthesis in cellulo and blocks bronchoconstriction and inflammation in vivo. Biochem. Pharmacol. 112 (2016), 60–71.
27. [27] Soderberg, O., Gullberg, M., Jarvius, M., Ridderstrale, K., Leuchowius, K.J., Jarvius, J., et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat. Methods 3 (2006), 995–1000.
28. [28] Hoffmann, M., Lopez, J.J., Pergola, C., Feisst, C., Pawelczik, S., Jakobsson, P.J., et al. Hyperforin induces Ca(2+)-independent arachidonic acid release in human platelets by facilitating cytosolic phospholipase A(2) activation through select phospholipid interactions. Biochim. Biophys. Acta 2010 (1801), 462–472.
29. [29] Pergola, C., Gerstmeier, J., Monch, B., Caliskan, B., Luderer, S., Weinigel, C., et al. The novel benzimidazole derivative BRP-7 inhibits leukotriene biosynthesis in vitro and in vivo by targeting 5-lipoxygenase-activating protein (FLAP). Br. J. Pharmacol. 171 (2014), 3051–3064.
30. [30] Rao, T.S., Currie, J.L., Shaffer, A.F., Isakson, P.C., In vivo characterization of zymosan-induced mouse peritoneal inflammation. J. Pharmacol. Exp. Ther. 269 (1994), 917–925.
31. [31] Kolaczkowska, E., Shahzidi, S., Seljelid, R., van Rooijen, N., Plytycz, B., Early vascular permeability in murine experimental peritonitis is co-mediated by resident peritoneal macrophages and mast cells: crucial involvement of macrophage-derived cysteinyl-leukotrienes. Inflammation 26 (2002), 61–71.
32. [32] Werz, O., Burkert, E., Samuelsson, B., Radmark, O., Steinhilber, D., Activation of 5-lipoxygenase by cell stress is calcium independent in human polymorphonuclear leukocytes. Blood 99 (2002), 1044–1052.
33. [33] Werz, O., Klemm, J., Samuelsson, B., Radmark, O., Phorbol ester up-regulates capacities for nuclear translocation and phosphorylation of 5-lipoxygenase in Mono Mac 6 cells and human polymorphonuclear leukocytes. Blood 97 (2001), 2487–2495.
34. [34] Surette, M.E., Dallaire, N., Jean, N., Picard, S., Borgeat, P., Mechanisms of the priming effect of lipopolysaccharides on the biosynthesis of leukotriene B4 in chemotactic peptide-stimulated human neutrophils. FASEB J. 12 (1998), 1521–1531.
35. [35] Carter, G.W., Young, P.R., Albert, D.H., Bouska, J., Dyer, R., Bell, R.L., et al. 5-Lipoxygenase inhibitory activity of zileuton. J. Pharmacol. Exp. Ther. 256 (1991), 929–937.
36. [36] Miller, D.K., Gillard, J.W., Vickers, P.J., Sadowski, S., Leveille, C., Mancini, J.A., et al. Identification and isolation of a membrane protein necessary for leukotriene production. Nature 343 (1990), 278–281.
37. [37] Fischer, L., Steinhilber, D., Werz, O., Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13,610. Br. J. Pharmacol. 142 (2004), 861–868.
38. [38] Werz, O., Szellas, D., Henseler, M., Steinhilber, D., Nonredox 5-lipoxygenase inhibitors require glutathione peroxidase for efficient inhibition of 5-lipoxygenase activity. Mol. Pharmacol. 54 (1998), 445–451.
39. [39] Mancini, J.A., Blood, K., Guay, J., Gordon, R., Claveau, D., Chan, C.C., et al. Cloning, expression, and up-regulation of inducible rat prostaglandin e synthase during lipopolysaccharide-induced pyresis and adjuvant-induced arthritis. J. Biol. Chem. 276 (2001), 4469–4475.
40. [40] Lam, B.K., Penrose, J.F., Freeman, G.J., Austen, K.F., Expression cloning of a cDNA for human leukotriene C4 synthase, an integral membrane protein conjugating reduced glutathione to leukotriene A4. Proc. Natl. Acad. Sci. 91 (1994), 7663–7667.
41. [41] Claveau, D., Sirinyan, M., Guay, J., Gordon, R., Chan, C.C., Bureau, Y., et al. Microsomal prostaglandin E synthase-1 is a major terminal synthase that is selectively up-regulated during cyclooxygenase-2-dependent prostaglandin E2 production in the rat adjuvant-induced arthritis model. J. Immunol. 170 (2003), 4738–4744.
42. [42] Steinhilber, D., Hoshiko, S., Grunewald, J., Radmark, O., Samuelsson, B., Serum factors regulate 5-lipoxygenase activity in maturating HL60 cells. Biochim. Biopys. Acta 1178 (1993), 1–8.
43. [43] Feisst, C., Pergola, C., Rakonjac, M., Rossi, A., Koeberle, A., Dodt, G., et al. Hyperforin is a novel type of 5-lipoxygenase inhibitor with high efficacy in vivo. Cell. Mol. Life Sci. 66 (2009), 2759–2771.
44. [44] Stock, N.S., Bain, G., Zunic, J., Li, Y., Ziff, J., Roppe, J., et al. 5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor. J. Med. Chem. 54 (2011), 8013–8029.
45. [45] Werz, O., Steinhilber, D., Development of 5-lipoxygenase inhibitors–lessons from cellular enzyme regulation. Biochem. Pharmacol. 70 (2005), 327–333.
46. [46] Jakobsson, P.J., Morgenstern, R., Mancini, J., Ford-Hutchinson, A., Persson, B., Membrane-associated proteins in eicosanoid and glutathione metabolism (MAPEG). A widespread protein superfamily. Am. J. Respir. Crit. Care Med. 161 (2000), S20–S24.
47. [47] Steinhilber, D., Hofmann, B., Recent advances in the search for novel 5-lipoxygenase inhibitors. Basic Clin. Pharmacol. Toxicol. 114 (2014), 70–77.
48. [48] Hakonarson, H., Thorvaldsson, S., Helgadottir, A., Gudbjartsson, D., Zink, F., Andresdottir, M., et al. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA 293 (2005), 2245–2256.
49. [49] Helgadottir, A., Gretarsdottir, S., St Clair, D., Manolescu, A., Cheung, J., Thorleifsson, G., et al. Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. Am. J. Hum. Genet. 76 (2005), 505–509.
50. [50] Helgadottir, A., Manolescu, A., Thorleifsson, G., Gretarsdottir, S., Jonsdottir, H., Thorsteinsdottir, U., et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat. Genet. 36 (2004), 233–239.
51. [51] Hakonarson, H., Role of FLAP and PDE4D in myocardial infarction and stroke: target discovery and future treatment options. Curr. Treat Options Cardiovasc. Med. 8 (2006), 183–192.
52. [52] Samuelsson, B., Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 220 (1983), 568–575.
53. [53] Lammermann, T., Afonso, P.V., Angermann, B.R., Wang, J.M., Kastenmuller, W., Parent, C.A., et al. Neutrophil swarms require LTB4 and integrins at sites of cell death in vivo. Nature 498 (2013), 371–375.
54. [54] Gillard, J., Ford-Hutchinson, A.W., Chan, C., Charleson, S., Denis, D., Foster, A., et al. L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2 - dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor. Can. J. Physiol. Pharmacol. 67 (1989), 456–464.
55. [55] Muller-Peddinghaus, R., Fruchtmann, R., Ahr, H.J., Beckermann, B., Buhner, K., Fugmann, B., et al. BAY X1005, a new selective inhibitor of leukotriene synthesis: pharmacology and pharmacokinetics. J. Lipid Med. 6 (1993), 245–248.
56. [56] Brideau, C., Chan, C., Charleson, S., Denis, D., Evans, J.F., Ford-Hutchinson, A.W., et al. Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor. Can. J. Physiol. Pharmacol. 70 (1992), 799–807.
57. [57] Lorrain, D.S., Bain, G., Correa, L.D., Chapman, C., Broadhead, A.R., Santini, A.M., et al. Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation. Eur. J. Pharmacol. 640 (2010), 211–218.
58. [58] Bain, G., King, C.D., Schaab, K., Rewolinski, M., Norris, V., Ambery, C., et al. Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitor. Br. J. Clin. Pharmacol. 75 (2013), 779–790.